A new study from the University of Michigan Health System suggests that a compound in green tea may provide therapeutic benefits to people with rheumatoid arthritis.
When bile duct cancer cells were placed in the liver of animals with bile duct obstruction, they grew more rapidly than identical cells placed in animals without bile duct obstruction. In fact, half of the total liver mass of the rats with bile duct obstruction became replaced by cancer cells within three weeks compared to only 16 percent of that of animals without bile duct obstruction.
Access to antiretroviral therapy for advanced HIV infection in low- and middle-income countries continued to grow throughout 2006, with more than two million people living with HIV/AIDS receiving treatment in December 2006, a 54% increase over the 1.3 million people on treatment one year earlier in these countries.
Pfizer Canada Inc. announced that Health Canada has approved the cholesterol-lowering therapy Lipitor(R) (atorvastatin calcium) to reduce the risk of myocardial infarction in patients with clinically evident coronary heart disease.
The U.S. Food and Drug Administration (FDA) approved Humate-P (Antihemophilic Factor/von Willebrand Factor Complex) for the prevention of excessive bleeding during and after surgery in certain patients with mild to moderate and severe von Willebrand disease (vWD).
A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.
A rigorous, long-term study of quality of life in patients who underwent one of three common prostate cancer treatments found that each treatment affected men’s lives in different ways.
Biomedical researchers have identified a cellular protein that interferes with hepatitis C virus replication, a finding that ultimately may help scientists develop new drugs to fight the virus.
The clinical outcomes of the JIKEI HEART Study, the large-scale clinical trial headed by the Jikei University School of Medicine, was today published in the internationally renowned medical journal The Lancet.
A new study shows that aspirin therapy for coronary artery disease is four times more likely to be ineffective in women compared to men with the same medical history.